Corbus Pharma (CRBP) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization

Graphic logo of Corbus Pharma (CRBP)

Corbus Pharmaceuticals (CRBP) is currently focused on preparing the final stages of trials for its innovative conjugates. The business's environmental strategy is based on the safe recycling of laboratory waste and strict research ethics. This EV/EBITDA chart on GURU.Markets currently shows 0.00, complementing data on the staff of high-caliber scientists who are attracted to the company by flexible working conditions and stock option programs.

CRBP Corbus Pharmaceuticals Holdings, Inc.: Enterprise Value to Operating Income Before Depreciation in the range 11/23/2025 - 11/14/2026

CRBP (Corbus Pharmaceuticals Holdings, Inc.): analytical breakdowns and indicator data

- stock price and consensus target price:
Stock Quotes Corbus Pharmaceuticals|CRBP - Fair Value Consensus
- market capitalization indicators:
Market Value Corbus Pharmaceuticals, Inc.|CRBP - Total Enterprise Value
- book value of equity indicators:
Net Assets per Single Share Corbus Pharmaceuticals|CRBP - Accounting Capitalization|Market Capitalization to Book Value Ratio corbuspharma.com|CRBP - Cumulative Company Assets
- debt and liquidity data:
Debt to Equity Corbus Pharmaceuticals|CRBP - Long-Term Liabilities to Capital|Short-Term Debt to Equity Corbus Pharma|CRBP - Company Debts|Debt to Book Capitalization Ratio Corbus Pharmaceuticals, Inc.|CRBP - Long-Term Debt|Company Short-Term Debts Corbus Pharmaceuticals|Quick Liquidity Indicator corbuspharma.com
- business earnings and investment ratios data:
CRBP - Company Net Income|Future Profit Corbus Pharmaceuticals|CRBP - Company Value to Net Income|Projected Price to Earnings Corbus Pharmaceuticals|CRBP - Company Value to Earnings Growth Ratio|EV/EBITDA Multiple Corbus Pharmaceuticals Holdings, Inc.|CRBP - Income before deduction of interest, taxes and amortization|Net earnings per share (EPS TTM) Corbus Pharmaceuticals|CRBP - Net earnings per one share for the last twelve months|Year-over-year earnings per share growth for the last twelve months corbuspharma.com|CRBP - Earnings per share increase in current year|Earnings growth forecast for next year Corbus Pharmaceuticals
- sales and revenue indicators:
CRBP - Revenue and Sales Volume|Company Projected Revenue Corbus Pharma|CRBP - Price-to-Sales Ratio|Forward Price-to-Revenue Multiple Corbus Pharmaceuticals, Inc.
Summary company analytics:CRBP (Corbus Pharmaceuticals Holdings, Inc.)
Original product of Corbus Pharmaceuticals Holdings

Corbus Pharmaceuticals (CRBP) is investing significant funds into oncology research, anticipating future superprofits from its proprietary therapy. This EV/EBITDA metric correlates the total enterprise value with the business's ability to generate cash flow before taxes and interest. This chart's price action allows for the filtering of speculative noise, revealing actual undervaluation or the risk of capital freeze. A stable trend confirms the resilience of the model amidst high fixed costs.

Competitor analysis

Incyte Corporation - Enterprise Value to EBITDA Ratio|hutch-med.com (HCM) - Company Value to EBITDA|NUVB - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Company Value to EBITDA Day One Biopharmaceuticals, Inc.|Monopar Therapeutics (MNPR) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Enterprise Value to Operating Income Before Depreciation INBX|IMAB (i-mabbiopharma.com) - EV/EBITDA Multiple|Enterprise Value to EBITDA Ratio fennecpharma.com (FENC)|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Heron Therapeutics (HRTX)|NVCT - Company Value to EBITDA|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Coherus BioSciences, Inc CHRS|Cardiff Oncology, Inc. - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|BYSI - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Company Value to EBITDA bioatla.com|LIXT: EV/EBITDA Multiple|Enterprise Value to EBITDA Multiple Citius Pharmaceuticals CTXR|Enterprise Value to EBITDA Ratio CLRB|Company Value to EBITDA BioLineRx Ltd. BLRX|Enterprise Value to EBITDA Ratio CANF (Can-Fite BioPharma)|APRE (Aprea) - Business Value to Operating Income Before Depreciation|Kazia Therapeutics Limited - Enterprise Value to EBITDA Ratio|Enterprise Value to Operating Income Before Depreciation Ratio SLXN (Silexion)|NuCana - EV/EBITDA Multiple|Business Value to Operating Income Before Depreciation CMRX (Chimerix, Inc)|CYCC: EV/EBITDA Multiple|Company Value to EBITDA G1 Pharma (GTHX)|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Kronos Bio|KTRA: Business Value to Operating Income Before Depreciation|EV/EBITDA Multiple ONCT|EV/EBITDA Multiple Portage Biotech Corp (PRTG)